Q-omics provides the consensus-scored FAM131C profile across patient tissues and cancer cell-line models. FAM131C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FAM131C is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, FAM131C RNA expression shows 18,762 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, COAD, and GBM as cancer lineages where FAM131C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM131C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM131C survival associations across molecular data types. FAM131C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM131C RNA expression–survival associations across cancer types. High FAM131C expression shows unfavorable associations in LUAD, UCEC, MESO and COAD, but favorable associations in KIRP and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FAM131C RNA expression.
This table summarizes FAM131C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM131C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM131C shows lower tumor expression in THCA and higher tumor expression in COAD, LUSC, LUAD, BLCA and HNSC. The COAD box plot shows higher FAM131C RNA expression in tumor versus normal tissue (log2 FC = +0.714, t-test p < 0.001).
This table shows molecular features associated with FAM131C in patient tissues and cancer cell lines. In patient samples, FAM131C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM131C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
